🇺🇸 Comparator: timolol in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 3
Most-reported reactions
- Chest Pain — 1 report (33.33%)
- Cough — 1 report (33.33%)
- Influenza Like Illness — 1 report (33.33%)
Other Ophthalmology approved in United States
Frequently asked questions
Is Comparator: timolol approved in United States?
Comparator: timolol does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Comparator: timolol in United States?
Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.